Lipid lowering in patients 75 years and older

More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date – ezetimibe. Since then, ezetimibe has become a wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Makhmudova, Umidakhon, Schulze, P Christian, Davis, Harry R, Weingärtner, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554361/
https://www.ncbi.nlm.nih.gov/pubmed/34754397
http://dx.doi.org/10.4330/wjc.v13.i10.526
_version_ 1784591781981061120
author Makhmudova, Umidakhon
Schulze, P Christian
Davis, Harry R
Weingärtner, Oliver
author_facet Makhmudova, Umidakhon
Schulze, P Christian
Davis, Harry R
Weingärtner, Oliver
author_sort Makhmudova, Umidakhon
collection PubMed
description More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date – ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.
format Online
Article
Text
id pubmed-8554361
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85543612021-11-08 Lipid lowering in patients 75 years and older Makhmudova, Umidakhon Schulze, P Christian Davis, Harry R Weingärtner, Oliver World J Cardiol Minireviews More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date – ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines. Baishideng Publishing Group Inc 2021-10-26 2021-10-26 /pmc/articles/PMC8554361/ /pubmed/34754397 http://dx.doi.org/10.4330/wjc.v13.i10.526 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Makhmudova, Umidakhon
Schulze, P Christian
Davis, Harry R
Weingärtner, Oliver
Lipid lowering in patients 75 years and older
title Lipid lowering in patients 75 years and older
title_full Lipid lowering in patients 75 years and older
title_fullStr Lipid lowering in patients 75 years and older
title_full_unstemmed Lipid lowering in patients 75 years and older
title_short Lipid lowering in patients 75 years and older
title_sort lipid lowering in patients 75 years and older
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554361/
https://www.ncbi.nlm.nih.gov/pubmed/34754397
http://dx.doi.org/10.4330/wjc.v13.i10.526
work_keys_str_mv AT makhmudovaumidakhon lipidloweringinpatients75yearsandolder
AT schulzepchristian lipidloweringinpatients75yearsandolder
AT davisharryr lipidloweringinpatients75yearsandolder
AT weingartneroliver lipidloweringinpatients75yearsandolder

Ejemplares similares